Takeda withdraws FDA application for dengue vaccine; Eisai exec who helped lead Alzheimer's drug development to retire

Taking stock of the drug industry, from the lab to the medicine chest

July 11, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Chantal Heijnen for STAT STAT+ | Eisai executive who helped lead development of Alzheimer's drug to retire Ivan Cheung will be replaced in his capacity as head of the company's Alzheimer's unit by Keisuke Naito, son of the company's CEO. By Brittany Trang Takeda withdraws application for dengue vaccine from FDA The company said in a press release that it will review whether to proceed with trying to bring the dengue vaccine to the U.S. market. By Helen Branswell STAT+ | How UnitedHealth's acquisition of a popular Medicare Advantage algorithm sparked internal dissent over denied care An investigation of UnitedHealth Group's NaviHealth reveals its algorithm is a focal point for determining Medicare Advantage coverage. By Casey Ross and Bob Herman Sophie Park/The New York Times White House announces new plan to address the growing threat of xylazine in overdose crisis The White House unveiled a plan to address the growing presence of xylazine, a veterinary tranquilizer, in the country's illicit drug supply.  By Lev Facher

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser